top ad


12/09/2017 01:14:09 AM

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

- Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry
- LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products
- Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications

Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as well as existing products and applications, and allows LXRP and stakeholders to participate, on a global scale, in the medical marijuana market that is expected to reach a value of USD $55.8 billion by 2025 according to a report by Grand View Research, Inc. (

John Docherty, President of Lexaria Bioscience Corp., recently issued a video clip discussing the company’s innovative technology that allows for the enhanced flavor and faster absorption of edible products. He discussed opportunities LXRP stakeholders have in commercial applications via third-party licensing in order to leverage the innovative technology to improve delivery and performance of various products in a cost-effective manner (

LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids and carriers, then dehydrated in order to not only accommodate delivery via taste receptors but also accelerate effects as well as intestinal absorption (with accelerated rate of absorption up to 10 times), providing an improved consumer experience and lower cost per dose.

Lexaria’s CBD-based products include tablets, protein energy bars, teas and TurboCBD™ high absorption hemp oil capsules. To date, LXRP has signed royalty agreements with several companies in the United States and Canada for licensed use of its patented technology.

Lexaria is the only company in the world that has been awarded a patent in the United States, Canada, and Australia, for the improved (oral or ingestible) delivery of all non-psychoactive cannabinoids (including liquid emulsions, tablets, capsules, etc.), in addition to delivery of THC and other psychoactive cannabinoids. Additional patents are pending in 40 more countries for use worldwide in an array of applications.

LXRP’s technology is a complimentary layer that works within all research and development applications of cannabinoids in the growing global market. As a result, the technology enables efficacy and results in delivery across a broad spectrum of uses.

For more information, visit the company’s website at

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

top ad
top ad
top ad

Join Now! - 100% FREE

I agree by the terms and conditions